Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Cogent Biosciences, Inc. Banner

Cogent Biosciences, Inc.

COGT Stock Analysis

Page title

Section title

About Cogent Biosciences, Inc.

Biotechnology
Healthcare

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Cogent Biosciences, Inc. Key Metrics

Market Cap
$1B
52 Weeks Low
$3.67
52 Weeks High
$12.14
P/B
2.98x
P/E
-4.90x
P/S
219.57x

Upcoming Events

    COGT Analyst Forecasts

    ‌
    ‌

    COGT Financials

    COGT Income Statement Key Metrics

    • Revenue(TTM)5.59 M
    • Gross Profit(TTM)1.79 M
    • EBITDA(TTM)-241.66 M
    • Net Income(TTM)-227.05 M
    • EPS Diluted(TTM)-2.48

    Decode COGT's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    COGT earnings and revenue history

    COGT Return on Equity

    See how efficiently COGT generates profit for it's shareholders.

    -74.63%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of COGT (-0.746) is higher than the average of its peers (-0.767).

    Return on Equity Growth

    COGT's Return on Equity has grown significantly over the past 10 years, increasing by over 25.76%.

    COGT Revenue Growth

    See how COGT has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    COGT's revenue has shown poor growth over the past 10 years, increasing by only -100%.